Log in to your Inderes Free account to see all free content on this page.
Spago Nanomedical
0.11 SEK
+3.96 %
Less than 1K followers
SPAGO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+3.96 %
-4.98 %
-29.43 %
-44.49 %
-24.39 %
-21.59 %
-75.37 %
-98.24 %
-98.70 %
Spago Nanomedical is active in biotechnology. The company develops nanomedicine for the diagnosis and treatment of life-threatening diseases. The company's main activities are focused on developing a cancer-selective contrast agent for magnetic resonance imaging (MRI), as well as a product for radionuclide treatment of cancer. Both of these projects are based on proprietary nanomaterials. The largest operations are in the Nordic market, with the headquarters located in Lund.
Read moreMarket cap
69.47M SEK
Turnover
68.35K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
4.2.
2026
Annual report '25
6.5.
2026
Interim report Q1'26
10.6.
2026
General meeting '26
All
Press releases
ShowingAll content types
Spago Nanomedical announces outcome of oversubscribed rights issue
BioStock: Video from Spago Nanomedical's presentation at BioStock Life Science Summit 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio